Frontiers in nutrition · 2026
Role of enteral nutrition in the clinical care, management, and quality of life of patients with inflammatory bowel disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Qian, Zhu Qianlan, Chen Ruidong, Zhou Shuang, Tang Wen
Аннотация
BACKGROUND: Enteral nutrition (EN) is essential for Inflammatory Bowel Disease treatment. This applies mainly to Crohn's disease (CD) and ulcerative colitis (UC) patients. The study evaluated the impact of EN treatment on clinical, nutritional, inflammatory, and quality of life outcomes in IBD patients. This study aimed to examine the association between EN therapy's clinical, nutritional, inflammatory, and Quality of Life (QoL) effects on Inflammatory Bowel Disease patients.
METHODS: A retrospective study investigated 750 Chinese IBD patients. These patients had 400 CD and 350 UC diagnoses. Medical records provided data. EN formula, administration, calorie density, and duration were studied along with disease activity, nutritional markers including hemoglobin, albumin, and body mass index, and inflammatory indices like erythrocyte sedimentation rate. Validated IBDQ measures quality of life. Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score < 150 for CD patients and a Mayo score ≤ 2 (with no individual subscore > 1) for UC patients, assessed after completion of EN therapy. Chi-square and t-tests were used for statistical analysis, with a significance level of p < 0.05.
RESULTS: Baseline characteristics of 750 patients are comparable between groups. Elemental and semi-elemental formulas were more frequently prescribed in CD patients and were associated with higher caloric and protein intake (p < 0.05). Approximately 60% of patients achieved clinical remission after 6 ± 2 weeks of EN therapy (62.5% CD vs. 57.1% UC). Improvements in BMI, albumin, hemoglobin, and CRP were observed in patients receiving EN, along with increased IBDQ scores. Adverse effects were minor (8%). Full adherence (OR = 2.15, p < 0.001) and longer EN duration (>6 weeks) were independently associated with higher odds of remission and QoL improvement.
CONCLUSION: EN therapy corresponded with clinical remission, improved nutritional markers, and reduced inflammation in IBD patients, particularly those with CD. These findings support the potential role of EN as a complementary strategy in IBD management; however, prospective randomized trials are further confirming these associations and standardize therapeutic protocols.
METHODS: A retrospective study investigated 750 Chinese IBD patients. These patients had 400 CD and 350 UC diagnoses. Medical records provided data. EN formula, administration, calorie density, and duration were studied along with disease activity, nutritional markers including hemoglobin, albumin, and body mass index, and inflammatory indices like erythrocyte sedimentation rate. Validated IBDQ measures quality of life. Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score < 150 for CD patients and a Mayo score ≤ 2 (with no individual subscore > 1) for UC patients, assessed after completion of EN therapy. Chi-square and t-tests were used for statistical analysis, with a significance level of p < 0.05.
RESULTS: Baseline characteristics of 750 patients are comparable between groups. Elemental and semi-elemental formulas were more frequently prescribed in CD patients and were associated with higher caloric and protein intake (p < 0.05). Approximately 60% of patients achieved clinical remission after 6 ± 2 weeks of EN therapy (62.5% CD vs. 57.1% UC). Improvements in BMI, albumin, hemoglobin, and CRP were observed in patients receiving EN, along with increased IBDQ scores. Adverse effects were minor (8%). Full adherence (OR = 2.15, p < 0.001) and longer EN duration (>6 weeks) were independently associated with higher odds of remission and QoL improvement.
CONCLUSION: EN therapy corresponded with clinical remission, improved nutritional markers, and reduced inflammation in IBD patients, particularly those with CD. These findings support the potential role of EN as a complementary strategy in IBD management; however, prospective randomized trials are further confirming these associations and standardize therapeutic protocols.